Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis in Kuwait

Abstract

Objective Biologics are indicated in rheumatoid arthritis (RA) in case of persistent high disease activity despite conventional disease-modifying anti-rheumatic drugs (cDMARDs) or patients with contraindications to cDMARDs or poor prognostic factors. The purpose of this study was to compare the prescription rates of biologics in Kuwaiti and non-Kuwaiti patients and to assess whether this had an impact on disease activity and quality of life in RA patients. Methods Data were extracted from the Kuwait Registry for Rheumatic Diseases. Adult patients who satisfied the ACR classification criteria for RA from four major hospitals in Kuwait were evaluated from February 2013 through May 2018. The treatment agents, disease activity, and quality of life of Kuwaiti patients were compared with non-Kuwaiti patients. Results A total of 1651 RA patients were included; 806 (48.8%) were Kuwaiti patients. Among Kuwaiti patients, 62.5% were on biologic drugs in comparison with 14% of non-Kuwaiti patients. In comparison with non-Kuwaiti patients, Kuwaiti patients had significantly lower numbers of swollen joints (p < 0.001) and disease activity score-28 scores (p = 0.02) and less steroid use (p < 0.001) yet a significantly higher health assessment questionnaire-disability index (p < 0.001). Regression analysis showed that DAS-28 scores were significantly associated with the treatment type (p < 0.001) and that nationality was significantly predictive of the treatment type (p < 0.001). Conclusion In the setting of easy accessibility to treatment for Kuwaiti patients, biologics were prescribed by rheumatologists at a higher rate than for non-Kuwaitis. This may explain the lower disease activity and the lower rate of steroid use in Kuwaiti patients than non-Kuwaitis. Key points • Significant discrepancies in the rates of prescribing biologic therapies between KP and NKP in Kuwait were observed. • Several treatment outcomes were significantly better in the KP group than in the NKP group even after adjustment of confounding factors. • The poor access to biologic therapies was suggested to limit the effectiveness of RA treatments in the NKP group.

Do Drug Accessibility and OOP Burden Affect Health-Related Quality of Life of Patients With Chronic Diseases? — EQ-5D-5L Evaluation Evidence From Five Districts in China

“…Based on this, this study explores the relationship between drug accessibility and HRQoL of patients with chronic diseases, and finds that the increase in the accessibility of medicines has significant positive impact on the health utility value of patients with chronic diseases. This assumption will be in line with other studies: Kuwaiti patients with rheumatoid arthritis have significantly reduced joint swelling and reduced disease activity due to the higher rate of biomedicine use, and the health assessment questionnaire scores higher (40). In order to ensure the accessibility of medicines, a number of studies have provided suggestions for national medicine policies.…”

A Review of the Prevalence and Unmet Needs in the Management of Rheumatoid Arthritis in Africa and the Middle East

“…However, management practices for RA, healthcare infrastructure, regulatory approval processes and the level of financial burden on patients vary considerably across countries in Africa and the Middle East [ 34 , 39 ]. A study in Kuwait reported lower disease activity and a positive impact on overall physical function in patients with easy access to biologic DMRDs compared with those without easy access [ 57 ]. Similar results were observed in a study in the United Arab Emirates where only 43% of patients received DMARDs [ 55 ], underlining the importance of easy access to highly effective treatments.…”

Network analysis and transcriptome profiling in peripheral blood mononuclear cells of patients with rheumatoid arthritis

“…In RA, as a chronic disease, the presentation and course of the disease differ among individual patients. In recent studies, gene detection in RA has been frequently discussed, but the results were rarely combined with clinical indicators and the patients' quality of life ( 33 , 34 ).…”